As of September 30, 2026, Cipher Pharmaceuticals, Inc. carries a market capitalization of 247.80M, placing it among publicly traded companies globally. Its enterprise value stands at 233.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 247.80M |
| Enterprise Value | 233.12M |
Cipher Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 18, 2027.
| Earnings Date | 3/18/2027 |
As of September 30, 2026, Cipher Pharmaceuticals, Inc. has 25.42M shares outstanding.
| Shares Outstanding | 25.42M |
As of September 30, 2026, Cipher Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 7.19. The price-to-sales ratio is 4.99, and the price-to-book ratio stands at 1.69.
| PE Ratio | 7.19 |
| PS Ratio | 4.99 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 4.05 |
| P/FCF Ratio | 10.63 |
| P/OCF Ratio | 9.98 |
As of September 30, 2026, Cipher Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 8.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 233.12M versus a market cap of 247.80M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 4.71 |
| EV / EBITDA | 8.04 |
| EV / EBIT | 10.69 |
As of September 30, 2026, Cipher Pharmaceuticals, Inc. maintains a current ratio of 1.99, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.44, indicating conservative leverage, while an interest coverage ratio of 568.76 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.99 |
| Quick Ratio | 1.56 |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 0.02 |
| Interest Coverage | 568.76 |
Over the twelve months ended September 30, 2026, Cipher Pharmaceuticals, Inc. posted a return on equity (ROE) of 26.42, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 21.78, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.15M in revenue per employee across its workforce of 43.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.23 indicates how many times Cipher Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 26.42 |
| Return on Assets (ROA) | 21.78 |
| Revenue Per Employee | 1.15M |
| Employee Count | 43.00 |
| Inventory Turnover | 1.23 |
Over the twelve months ended September 30, 2026, Cipher Pharmaceuticals, Inc. recorded an income tax benefit of -11.02M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 23.36M, leaving 34.38M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -11.02M |
As of the close on November 16, 2026, Cipher Pharmaceuticals, Inc.'s stock has gained approximately 3.12% over the past 52 weeks. The 50-day moving average sits at 9.80, while the 200-day moving average is 11.28.
| 52-Week Price Change | 3.12% |
| 50-Day Moving Average | 9.80 |
| 200-Day Moving Average | 11.28 |
Over the twelve months ended September 30, 2026, Cipher Pharmaceuticals, Inc. generated 49.49M in revenue and converted that into 34.38M in net income, yielding earnings per share of 1.32. EBITDA reached 29.01M, while operating income came in at 19.97M.
| Revenue | 49.49M |
| Gross Profit | 40.27M |
| Operating Income | 19.97M |
| Pretax Income | 23.36M |
| Net Income | 34.38M |
| EBITDA | 29.01M |
| EBIT | 21.81M |
| Earnings Per Share (EPS) | 1.32 |
As of September 30, 2026, Cipher Pharmaceuticals, Inc. holds 15.33M in cash and equivalents against 644,000.00 in total debt, resulting in a net debt position of -15.33M. Total book value stands at 146.31M, with working capital of 21.41M providing operational flexibility.
| Cash & Cash Equivalents | 15.33M |
| Total Debt | 644,000.00 |
| Net Debt | -15.33M |
| Equity (Book Value) | 146.31M |
| Book Value Per Share | 5.76 |
| Working Capital | 21.41M |
Cipher Pharmaceuticals, Inc. produced 24.76M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -947,000.00 in capital expenditures, free cash flow totaled 23.82M - equivalent to 0.94 per share.
| Operating Cash Flow | 24.76M |
| Capital Expenditures | -947,000.00 |
| Free Cash Flow | 23.82M |
| FCF Per Share | 0.94 |
Over the twelve months ended September 30, 2026, Cipher Pharmaceuticals, Inc. posted a gross margin of 81.36, reflecting its pricing power and cost economics. The operating margin of 40.35 and net profit margin of 69.47 provide insight into operational efficiency.
| Gross Margin | 81.36 |
| Operating Margin | 40.35 |
| Pretax Margin | 47.20 |
| Profit Margin | 69.47 |
| EBITDA Margin | 58.61 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 9.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Cipher Pharmaceuticals, Inc. shareholders.
| Shareholder Yield | 6.75 |
| FCF Yield | 9.41 |
As of September 30, 2026, Cipher Pharmaceuticals, Inc. has an Altman Z-Score of 10.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.48 |
Already premium?